UnitedHealth Analysts Boost Their Forecasts Following Upbeat Earnings

UnitedHealth Group UNH reported better-than-expected second-quarter earnings on Tuesday.

The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from Benzinga Pro. UnitedHealth’s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare.

UnitedHealth expects a 2024 net profit of $15.95-$16.40 per share to reflect the classification to held for sale of its remaining South America operations, and the estimated Change Healthcare cyberattack impacts versus the prior estimate of $17.60-$18.20.

UnitedHealth shares gained 6.5% to close at $548.87 on Tuesday.

Pre-IPO Offer: Get A Piece Of A Nearly $5T Global Opportunity By Joining BOXABL As An Early Shareholder At Just $0.80/Share

Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.

Share Price: $0.80

Min. Investment: $1,000

Valuation: $3.5B

These analysts made changes to their price targets on UnitedHealth after the company released quarterly results.

Morgan Stanley analyst Ricky Goldwasser maintained UnitedHealth with an Overweight rating and boosted the price target from $595 to $615.
Baird analyst Michael Ha maintained the stock with an Outperform rating, while increasing the price target from $597 to $640.
Truist Securities analyst David Macdonald maintained UnitedHealth with a Buy rating, while boosting the price target from $600 to $640.
Jefferies analyst David Windley upgraded UnitedHealth from Hold to Buy and increased the price target from $481 to $647.

Read Next: